




# CELL SURGICAL NETWORK<sup>®</sup>

# Neurology


## Background

The Cell Surgical Network investigates the use of autologous adipose derived stromal vascular fraction (SVF, which contains pre-adipocytes, peri-vascular, and hematopoietic stem cells). This work is conducted under IRB approved protocols throughout our affiliate centers around the world. Patient data is collected and follow ups conducted every 3 months to determine efficacy of the cell surgical procedure. This data was collected by CSN affiliates between 2013 and 2017

## Multiple Sclerosis



Multiple Sclerosis-CSN Improvement



### Multiple Sclerosis Success Rate



MS Patients experienced a 52% reduction in MISS-29 scores over 2 years

## Stroke

### Stroke Success Rate



■ Yes (55%) ■ No (45%)

## Parkinson's Disease

### Parkinson's Disease Success Rate



■ Yes (64.80%) ■ No (35.20%)

# Muscular Dystrophy


Muscular Dystrophy Success Rate



■ Yes (64.30%) ■ No (35.70%)

# Cerebral Palsy

Cerebral Palsy Success Rate



■ Yes (77.80%) ■ No (22.20%)



The success rates presented above represent a patient population of over 400 that all underwent point of care stromal vascular fraction procedures. SVF procedures under the Cell Surgical Network's IRB approved protocols can yield between 10 to 40 million stem cells.

While point of care SVF appears to be quite effective in many cases, we understand that many of these chronic neurological conditions require many more than just 40 million stem cells.

The Cell Surgical Network's Affiliates can now bank their patients' cells; cryopreserving and expanding hundreds of millions of autologous stem cells. These cells are banked in an FDA registered lab and sent back under IRB approved protocol to participating physicians' offices in the USA, immediately ready for deployment. The sterility of the Cells On Ice program is routinely tested and ensured at each point in the process. The ability to utilize Cells On Ice offers physicians a unique ability to investigate the administration of the optimal dosing to treat the specific needs of each patient and their unique condition.

## CSN Registry and Data Collection

The Cell Surgical Network collects all of its patients' data in a HIPPA compliant online database. This allows us to study the safety and efficacy of every procedure. The database follows up with patients the first month after their cell surgery and every 3 months after for up to 5 years.



### Patient Population Brief Overview

CSN Average Age



■ Male (53.80%) ■ Female (46.20%)

